A retrospective database analysis of patients with chronic hepatitis C virus (HCV) infection who were administered elbasvir/grazoprevir (ZEPATIER) in the US Department of Veterans Affairs (VA) healthcare system

Trial Profile

A retrospective database analysis of patients with chronic hepatitis C virus (HCV) infection who were administered elbasvir/grazoprevir (ZEPATIER) in the US Department of Veterans Affairs (VA) healthcare system

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Elbasvir/grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Apr 2017 New trial record
    • 21 Apr 2017 Results from this trial were presented at the The International Liver Congress 2017, according to a Merck and Co. media release.
    • 21 Apr 2017 Results published in a Merck and Co. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top